Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model
暂无分享,去创建一个
[1] G. Gildengorin,et al. Current cervical neoplasia screening practices of obstetrician/gynecologists in the US. , 2005, American journal of obstetrics and gynecology.
[2] M. Weinstein,et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine , 2003, International journal of cancer.
[3] C. Wheeler,et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. , 2006, Vaccine.
[4] S. Collins,et al. A critique of cohort studies examining the role of human papillomavirus infection in cervical neoplasia , 2002, BJOG : an international journal of obstetrics and gynaecology.
[5] S. Wacholder,et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. , 2005, The Journal of infectious diseases.
[6] Lydia P. Howell,et al. NATURAL HISTORY OF CERVICAL SQUAMOUS INTRAEPITHELIAL LESIONS: A META‐ANALYSIS , 1998, Obstetrics and gynecology.
[7] M. Nygård,et al. Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian Coordinated Cervical Cancer Screening Program , 2005, Cancer Causes & Control.
[8] K. Holmes,et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection , 1992, The New England journal of medicine.
[9] T. Iannicelli,et al. Intramuscular interferon‐β treatment of cervical intraepithelial neoplasia II associated with human papillomavirus infection , 1994 .
[10] S. Ebrahim,et al. Use of cervical cancer screening among insured women: the extent of missed opportunities. , 2005, Health policy.
[11] Milton C Weinstein,et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. , 2004, Journal of the National Cancer Institute.
[12] N. Lurie,et al. Accuracy of self-report of mammography and Pap smear in a low-income urban population. , 1998, American journal of preventive medicine.
[13] J. Fowles,et al. Comparing Claims Data and Self-Reported Data with the Medical Record for Pap Smear Rates , 1997, Evaluation & the health professions.
[14] C. Wheeler,et al. A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.
[15] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[16] J. Berkhof,et al. Natural history and screening model for high‐risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands , 2005, International journal of cancer.
[17] J. Doorbar,et al. Human Papillomaviruses , 2006, Methods in Molecular Medicine.
[18] A. As. A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. , 1997, British journal of obstetrics and gynaecology.
[19] H. Dorn,et al. Morbidity from cancer in the United States. , 1953, Acta - Unio Internationalis Contra Cancrum.
[20] Y. Taketani,et al. IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia. , 2006, Cancer letters.
[21] D. A. Goldman,et al. Validity of Pap smear and mammogram self-reports in a low-income Hispanic population. , 1995, American journal of preventive medicine.
[22] L. Billingham,et al. The effect of directed biopsy on the atypical cervical transformation zone: assessed by digital imaging colposcopy , 1996, British journal of obstetrics and gynaecology.
[23] Erik J. Dasbach,et al. Model for Assessing Human Papillomavirus Vaccination Strategies , 2007, Emerging infectious diseases.
[24] J. Fortenberry,et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. , 2005, The Journal of infectious diseases.
[25] A. Friedman-kien. Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived). , 1995, American journal of obstetrics and gynecology.
[26] Heather Langhan Medical Student,et al. A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia , 2005 .
[27] K. Yamato,et al. Eradication of HPV post-surgical treatments, its correlation with specific types, types of surgery and the physical status. , 2004, Oncology reports.
[28] P. Porter,et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. , 2001, Cancer research.
[29] Cosette M Wheeler,et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.
[30] J. Meigs,et al. Uterine cervical carcinoma in Connecticut, 1935-1973: evidence for two classes of invasive disease. , 1976, Journal of the National Cancer Institute.
[31] Homa Keshavarz,et al. Hysterectomy surveillance -- United States 1994-1999. , 2002 .
[32] Philippe Vielh,et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening , 2003, BMJ : British Medical Journal.
[33] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[34] R. Hiatt,et al. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan , 2000, Journal of lower genital tract disease.
[35] B. Olgemöller,et al. Type-Specific Detection of Human Papillomaviruses in a Routine Laboratory Setting – Improved Sensitivity and Specificity of PCR and Sequence Analysis Compared to Direct Hybridisation , 2003, Clinical chemistry and laboratory medicine.
[36] D. Towsend. Persistent intraepithelial neoplasia after excision for cervical intraepithelial neoplasia grade III. , 1997, Obstetrics and gynecology.
[37] M. Plummer,et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.
[38] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[39] J. Holmes,et al. The cost-effectiveness of human papillomavirus screening for cervical cancer , 2005, The European Journal of Health Economics.
[40] I. Merkatz,et al. Clinical Usefulness of Computerized Colposcopy: Image Analysis and Conservative Management of Mild Dysplasia , 1992, Obstetrics and gynecology.
[41] D. Jeffe,et al. Effect of area poverty rate on cancer screening across US communities , 2006, Journal of Epidemiology and Community Health.
[42] M. Fahs,et al. Cost Effectiveness of Cervical Cancer Screening for the Elderly , 1992, Annals of Internal Medicine.
[43] R. Hiatt,et al. Concordance of self-reported data and medical record audit for six cancer screening procedures. , 1993, Journal of the National Cancer Institute.
[44] G. Bigras,et al. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13 842 women , 2005, British Journal of Cancer.
[45] A. Östör,et al. Natural history of cervical intraepithelial neoplasia: a critical review. , 1993, International Journal of Gynecological Pathology.
[46] I. I. Kessler. Cervical cancer epidemiology in historical perspective. , 1974, The Journal of reproductive medicine.
[47] Guoyu Tao,et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. , 2004, Perspectives on sexual and reproductive health.
[48] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[49] Scott B. Cantor,et al. COLPOSCOPY FOR THE DIAGNOSIS OF SQUAMOUS INTRAEPITHELIAL LESIONS: A META‐ANALYSIS , 1998, Obstetrics and gynecology.
[50] Daron G Ferris,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.
[51] A. Giuliano,et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. , 2002, The Journal of infectious diseases.
[52] S Sudman,et al. Cognitive aspects of recalling and reporting health-related events: Papanicolaou smears, clinical breast examinations, and mammograms. , 1997, American journal of epidemiology.
[53] Shalini L Kulasingam,et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. , 2002, JAMA.
[54] C. Redman,et al. Loop diathermy excision of the cervical transformation zone in patients with abnormal cervical smears. , 1990, BMJ.
[55] A. Moscicki,et al. External genital warts: diagnosis, treatment, and prevention. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[56] M. Sherman,et al. Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection , 2004, Cancer Epidemiology Biomarkers & Prevention.
[57] M. Lehtinen,et al. Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses , 2006, PLoS medicine.
[58] A. Teyssié,et al. Persistence of human papillomavirus DNA in cervical lesions after treatment with diathermic large loop excision. , 1998, Infectious diseases in obstetrics and gynecology.
[59] M. Plummer,et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. , 2003, American journal of epidemiology.
[60] Michal Abrahamowicz,et al. The natural history of type-specific human papillomavirus infections in female university students. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[61] S. Syrjänen,et al. Age-specific incidence and clearance of high-risk human papillomavirus infections in women in the former Soviet Union , 2005, International journal of STD & AIDS.
[62] E. Dasbach,et al. Incidence and Duration of Cervical Human Papillomavirus 6, 11, 16, and 18 Infections in Young Women: An Evaluation from Multiple Analytic Perspectives , 2007, Cancer Epidemiology Biomarkers & Prevention.
[63] M. von Knebel Doeberitz,et al. Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. , 1999, Journal of clinical pathology.
[64] E. Dasbach,et al. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women , 2007, Infectious Agents and Cancer.
[65] C. Woodman,et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study , 2001, The Lancet.
[66] Nancy Breen,et al. Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey. , 2004, Preventive medicine.
[67] A. Glass,et al. Diagnoses and outcomes in cervical cancer screening: a population-based study. , 2004, American journal of obstetrics and gynecology.
[68] K. Syrjänen,et al. Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). , 1996, European journal of obstetrics, gynecology, and reproductive biology.
[69] V Beral,et al. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study , 2004, British Journal of Cancer.
[70] B. Quade,et al. In vivo cyclin E expression as a marker for early cervical neoplasia. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[71] C. Callahan,et al. Accuracy of self-reported health services use and patterns of care among urban older adults. , 1999, Medical care.
[72] C. Woodman,et al. Human papillomavirus infection and risk of progression of epithelial abnormalities of the cervix. , 1996, British Journal of Cancer.
[73] Elamin H Elbasha,et al. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. , 2006, Epidemiologic reviews.
[74] T. Wright,et al. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. , 2002, JAMA.
[75] M. Schiffman,et al. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. , 2001, Journal of the National Cancer Institute.
[76] O. Ahmadpour,et al. Management of Female Genital Warts with an Analog of Imiquimod 2% in Cream: A Randomized, Double‐Blind, Placebo‐Controlled Study , 1998, The Journal of dermatology.
[77] J. Coste,et al. Cost‐effectiveness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: Protocol of the study of the French Society of Clinical Cytology , 2001, Diagnostic cytopathology.
[78] Calum MacAulay,et al. Natural History of Cervical Intraepithelial Neoplasia , 2005, Acta Cytologica.
[79] J. Redburn,et al. Hysterectomy prevalence and adjusted cervical and uterine cancer rates in England and Wales , 2001, BJOG : an international journal of obstetrics and gynaecology.
[80] K. Cooper,et al. Biotinyl-Tyramide-Based In Situ Hybridization Signal Patterns Distinguish Human Papillomavirus Type and Grade of Cervical Intraepithelial Neoplasia , 2002, Modern Pathology.
[81] H. Ngan,et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[82] H. Shimada,et al. Uterine Cervical Dysplasia and Cancer: Identification of C-myc Status by Quantitative Polymerase Chain Reaction , 1998, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[83] L. Smart,et al. Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia , 2002, BJOG : an international journal of obstetrics and gynaecology.
[84] Johannes Haerting,et al. Screening for high‐grade cervical intra‐epithelial neoplasia and cancer by testing for high‐risk HPV, routine cytology or colposcopy , 2000, International journal of cancer.
[85] W. Lawrence,et al. Benefits and costs of using HPV testing to screen for cervical cancer. , 2002, JAMA.
[86] S. Quah,et al. Patient assessment of anogenital warts and the success of treatment with home applied therapy. , 2004, International journal of STD & AIDS.
[87] M. Stoler,et al. Detection of Multiple Human Papillomavirus Types in Condylomata Acuminata Lesions from Otherwise Healthy and Immunosuppressed Patients , 1999, Journal of Clinical Microbiology.
[88] G. Nuovo,et al. Human Papillomavirus Detection in Cervical Lesions Nondiagnostic for Cervical Intraepithelial Neoplasia: Correlation With Papanicolaou Smear, Colposcopy, and Occurrence of Cervical Intraepithelial Neoplasia , 1990, Obstetrics and Gynecology.
[89] C. Wheeler,et al. Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.
[90] Gillian D. Sanders,et al. Cost Effectiveness of a Potential Vaccine for Human papillomavirus , 2003, Emerging infectious diseases.
[91] A. Glass,et al. Response to "Use of cervical cancer screening among insured women: the extent of missed opportunities" [Health Policy 73 (2005) 194-201]. , 2006, Health policy.
[92] Adalsteinn D. Brown,et al. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. , 1999, JAMA.
[93] D T Janerich,et al. The screening histories of women with invasive cervical cancer, Connecticut. , 1995, American journal of public health.
[94] L. Koss,et al. Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas. , 2003, Human pathology.
[95] V. Kataja,et al. Prevalence of Genital Human Papillomavirus Infections in a Mass-Screened Finnish Female Population Aged 20–65 Years , 1990, International journal of STD & AIDS.
[96] P. de Cremoux,et al. Regression of Low-Grade Cervical Intraepithelial Neoplasia in Patients With HLA-DRB1*13 Genotype , 2004, Obstetrics and gynecology.
[97] B. Goff,et al. Large loop excision of the transformation zone in patients with exocervical squamous intraepithelial lesions. , 1994, European journal of gynaecological oncology.
[98] F. X. Bosch,et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.
[99] N. Kiviat,et al. Development and duration of human papillomavirus lesions, after initial infection. , 2005, The Journal of infectious diseases.
[100] P. Martin-Hirsch,et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. , 2004, Cancer treatment reviews.
[101] L. Stanberry,et al. Preface to the fifth edition , 2014 .
[102] J. Simpson,et al. Progression and Regression of Low‐grade Epithelial Abnormalities of the Cervix , 1997, The Australian & New Zealand journal of obstetrics & gynaecology.
[103] Kathleen R. Cho,et al. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. , 1996, Cancer research.
[104] A. Jemal,et al. Global Cancer Statistics , 2011 .
[105] S. Chow,et al. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. , 1999, Gynecologic oncology.
[106] Shalini L Kulasingam,et al. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. , 2003, JAMA.
[107] C. Wheeler,et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts , 1995, Journal of clinical microbiology.
[108] R. Sanson-Fisher,et al. Accuracy of patients' recall of pap and cholesterol screening. , 2001, Journal of lower genital tract disease.
[109] S. Tyring,et al. Genital warts and their treatment. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[110] W. Quint,et al. The role of genotype‐specific human papillomavirus detection in diagnosing residual cervical intraepithelial neoplasia , 2002, International journal of cancer.
[111] R. Detels,et al. Validity of self-reporting of episodes of external genital warts. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[112] M. Kosinski,et al. GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed‐side , 2007, Clinical pharmacology and therapeutics.
[113] D C McCrory,et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. , 2000, American journal of epidemiology.
[114] G. Lovelace,et al. Detection of human papillomavirus DNA by in situ hybridization and polymerase chain reaction in human papillomavirus equivocal and dysplastic cervical biopsies. , 1993, Human pathology.
[115] E. Lazcano-Ponce,et al. Prognostic factors related to cervical cancer survival in Mexican women , 2001, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[116] M. Lehtinen,et al. Stability over time of serum antibody levels to human papillomavirus type 16. , 1998, The Journal of infectious diseases.
[117] B. Wiatrak. Overview of recurrent respiratory papillomatosis , 2003, Current opinion in otolaryngology & head and neck surgery.
[118] Helen Trottier,et al. The epidemiology of genital human papillomavirus infection. , 2006, Vaccine.
[119] J. Murdoch,et al. Histological incomplete excision of CIN after large loop excision of the transformation zone (LLETZ) merits careful follow up, not retreatment , 1992, British journal of obstetrics and gynaecology.
[120] D. Sidransky,et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.
[121] H. Hoyer,et al. Cumulative 5‐year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high‐risk HPV and cytology testing in a primary screening setting , 2005, International journal of cancer.
[122] J. Salonen,et al. Prospective follow-up of cervical HPV infections: Life table analysis of histopathological, cytological and colposcopic data , 1989, European Journal of Epidemiology.
[123] T. Wright,et al. Treatment of Cervical Intraepithelial Neoplasia Using the Loop Electrosurgical Excision Procedure , 1992, Obstetrics and gynecology.
[124] I. Arany,et al. Effect of Interferon Therapy on Human Papillomavirus Copy Number in Patients With Condyloma Acuminatum , 1995, American Journal of the Medical Sciences.
[125] H. Welch,et al. The frequency of Pap smear screening in the United States , 2004, Journal of General Internal Medicine.
[126] L. Westergaard,et al. Severe cervical dysplasia. Control by biopsies or primary conization? A comparative study. , 1982, Acta obstetricia et gynecologica Scandinavica.
[127] A. Glass,et al. Pap screening in a U.S. health plan. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[128] S. Chow,et al. Loop electrosurgical excision procedure for conization of the uterine cervix. , 1994, Journal of the Formosan Medical Association = Taiwan yi zhi.